1. Home
  2. BCAB vs KLXE Comparison

BCAB vs KLXE Comparison

Compare BCAB & KLXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • KLXE
  • Stock Information
  • Founded
  • BCAB 2007
  • KLXE 2018
  • Country
  • BCAB United States
  • KLXE United States
  • Employees
  • BCAB N/A
  • KLXE N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • KLXE Oilfield Services/Equipment
  • Sector
  • BCAB Health Care
  • KLXE Energy
  • Exchange
  • BCAB Nasdaq
  • KLXE Nasdaq
  • Market Cap
  • BCAB 96.2M
  • KLXE 90.4M
  • IPO Year
  • BCAB 2020
  • KLXE N/A
  • Fundamental
  • Price
  • BCAB $2.08
  • KLXE $4.49
  • Analyst Decision
  • BCAB Strong Buy
  • KLXE Hold
  • Analyst Count
  • BCAB 2
  • KLXE 1
  • Target Price
  • BCAB $6.00
  • KLXE $4.50
  • AVG Volume (30 Days)
  • BCAB 1.6M
  • KLXE 92.5K
  • Earning Date
  • BCAB 11-08-2024
  • KLXE 11-04-2024
  • Dividend Yield
  • BCAB N/A
  • KLXE N/A
  • EPS Growth
  • BCAB N/A
  • KLXE N/A
  • EPS
  • BCAB N/A
  • KLXE N/A
  • Revenue
  • BCAB N/A
  • KLXE $769,700,000.00
  • Revenue This Year
  • BCAB N/A
  • KLXE N/A
  • Revenue Next Year
  • BCAB N/A
  • KLXE $3.17
  • P/E Ratio
  • BCAB N/A
  • KLXE N/A
  • Revenue Growth
  • BCAB N/A
  • KLXE N/A
  • 52 Week Low
  • BCAB $1.14
  • KLXE $4.18
  • 52 Week High
  • BCAB $4.02
  • KLXE $12.13
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 55.80
  • KLXE 33.44
  • Support Level
  • BCAB $1.87
  • KLXE $4.31
  • Resistance Level
  • BCAB $2.13
  • KLXE $4.59
  • Average True Range (ATR)
  • BCAB 0.12
  • KLXE 0.31
  • MACD
  • BCAB 0.00
  • KLXE -0.05
  • Stochastic Oscillator
  • BCAB 68.90
  • KLXE 8.92

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About KLXE KLX Energy Services Holdings Inc.

KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.

Share on Social Networks: